There are 2137 resources available
340P - Patient preferences for HER2-targeted treatment of advanced or metastatic breast cancer in the United States
Presenter: Carol Mansfield
Session: E-Poster Display
Resources:
Abstract
341P - Does race impact outcomes in triple negative breast cancer?
Presenter: Kevin Holcomb
Session: E-Poster Display
Resources:
Abstract
342P - Different modalities of detection breast cancer recurrences: A 5-year retrospective cohort study
Presenter: Diego Zara
Session: E-Poster Display
Resources:
Abstract
343P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Efficacy and safety preliminary results of the advanced breast cancer (ABC) patients (pts) cohort of the MOVIE study
Presenter: Thibault de La Motte Rouge
Session: E-Poster Display
Resources:
Abstract
344P - Clinical outcomes of platinum-based polichemotherapy in patients with advanced breast cancer: A 10-year single institutional experience
Presenter: Maria Alice Franzoi
Session: E-Poster Display
Resources:
Abstract
345P - Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
Presenter: Ursula Hasler-Strub
Session: E-Poster Display
Resources:
Abstract
346P - Phase I study of the liposomal formulation of eribulin (E7389-LF): Results from the HER2-negative breast cancer expansion
Presenter: Kenji Tamura
Session: E-Poster Display
Resources:
Abstract
347P - Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
Presenter: Martine Piccart
Session: E-Poster Display
Resources:
Abstract
348P - First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Daniel Eiger
Session: E-Poster Display
Resources:
Abstract
349TiP - EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nab-PTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
Presenter: Priyanka Sharma
Session: E-Poster Display
Resources:
Abstract